# Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation

> **NCT02037373** · — · TERMINATED · sponsor: **Octapharma** · enrollment: 43 (actual)

## Conditions studied

- Coagulopathy
- Endstage Liver Disease

## Interventions

- **BIOLOGICAL:** Octaplas™
- **BIOLOGICAL:** Plasma

## Key facts

- **NCT ID:** NCT02037373
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** FDA released requirement to complete study
- **Last updated:** 2018-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02037373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02037373, "Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02037373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*